Summary.-The presence or absence of lymphocytic mucopolysaccharides (MPS) is studied in 223 subjects: 100 normals (controls); 8 cancer patients cured for more than 6 years; 30 cancer patients at the start of their treatment; and 85 relatives of first degree consanguinity of these last patients. The data are studied by statistical and genetic analysis. The results confirm the findings reported earlier and show that the difference in the probability of a high frequency of leucocytic MPS between the relatives of cancer patients and the controls is highly significant. Furthermore, this probability in a relative of first degree of consanguinity of a cancer patient is more than three times greater than in an individual of the general population. Genetic segregation analysis shows that the high leucocytic MPS trait segregates in the families of cancer patients after a classic pattern of dominant autosomal inheritance. Applying Falconer's nomogram it is concluded that the whole of this phenotypic variation is of genetic origin. Its interrelationships with cancer are discussed and it is postulated that this disturbance of the lymphocytic MPS represents a subclinical variant, not known until now, of the clinical mucopolysaccaridoses.
IN a former study (Riesco and Leyton, 1971 ) one of us showed that the blood of patients with cancer contained a much higher proportion of leucocytes with acid mucopolysaccharides (MPS) than that of normal individuals, the difference between both groups in this respect being statistically extremely significant. It was established that the presence or absence of MPS in the leucocytes did not depend on the cancer having been treated or not, at least during periods before or shortly after treatment.
In view of this it was important to know whether the presence of MPS in the leucocytes of these patients was caused by cancer in its clinical state. Therefore we examined whether patients treated for cancer more than 6 years before, and with apparent clinical recovery, still showed increased MPS in their leucocytes. The leucocytic MPS were determined in 8 patients of this type, treated between 6 and 23 years previously (Table I ). It was found that the same leucocytic alteration as in untreated cancer patients, (Tables III and V) . In all of them the presence or absence of leucocytic MPS was studied. The method employed was the same as in our former study (Riesco and Leyton, 1971) . In every group the number of lymphocytes with or without MPS was compared (Table III) , as well as the number of subjects with normal or abnormal numbers of lvmphocytes without MPS (Table V) , and the results were treated statistically (Tables IV, VI and VII). In our former study (Riesco and Leyton, 1971) we analysed comparatively only the total number of lymphocytes with and without MPS in each clinical group. In the present study we also include the comparative analysis of the number of individuals with normal and subnormal numbers of negative lymphocytes.
For determining the normal number of negative lymphocytes in each individual in the analysis of the group of 100 normal subjects we applied two different approaches.
One, as shown in Table III, is that 89 25% of the total lymphocytes of 100 normal subjects are negative: in each individual 9000 of the 20 lymphocytes classified is 18, a figure that represents the normal limit of negative lymphocytes in each individual according to this approach. On the other hand, the study of the bimodal curve in the same group of 100 normal subjects shows that the antimode is located at 18 negative lymphocytes (Fig. 1) , between the majority group (77%) and the minority (23%) of negative lymphocytes. Both approaches for (Fig. 1) , i.e., when of the 20 lymphocytes, classified 18, 19 or 20 lymphocytes are negative (Group 0). An individual is considered as having a subnormal number of negative lymphocytes when of the 20 lymphocytes classified, 17 or less lymphocytes are negative.
The genetic study of the MPS trait was made by (a) segregation analysis by classic methods (Smith, 1956) ; (b) analysis of relative risks in the relatives of first degree of consanguinity by the method of Li (1961) . The analysis of the positive or negative MPS trait in the families studied included the cancer patients. Segregation analysis was irrespective of the distribution of the cancer patients within the families.
RESULTS
The results of the study are summed up in the Tables III and V. Table III shows that the percentage of lymphocytes without MPS in normal individuals (89.25%) is markedly higher than in cancer patients (42*50%), which supports the results of our former study (Riesco and Leyton, 1971) . Table V for the lvmphocytes of the 100 control subjects (Table III) , and had a proportion of abnormal lymphocytes almost three times that of the controls. relatives of the cancer patients (43.52%).
The statistical study of these differences also show%-ed a high significance (Table VI ). An extremely high significance was also found for the differences between the number of lymphocytes without MPS in the control group and in the healthy relatives of the cancer patients, in the parents (X2-141.0), as well as in the offspring (X2 -1 67X 1) of these patients (Table IV) . Lastly, as can be seen in Table VI , there is a significant difference in the frequency of individuals with a normal number of lymphocytes without MPS between controls and cancer patients as well as between controls and the healthy relatives of these patients, but there is no significant difference in this respect between cancer patients and their presumably healthy-relatives.
The statistical study of the increased proportion of leucocytic MPS in the families of cancer patients is given in Table IV , which shows that this proportion is 5*37 times greater in cancer patienits than in controls. The comparison between the proportion in patients and in controls is also statistically significant. The differences in proportion decrease between cancer patients and their relatives, and there is no significant difference between the patients and their parents. When the genetic study of the leucocytic MPS is analysed using quantitative genetics after the method of Li (1961) (McKusick, 1969) , leads us to speculate on the possibility that the alteration in leucocytic MPS which we have described represents a variant of these disorders of lesser, subclinical magnitude. This subclinical entity, more frequent than the clinical mucopolysaccharidoses, would be apparently asymptomatic and for the moment its detection is possible only through the cytochemical study of the leucocytes in the peripheral blood.
The already reported interrelationships of this subclinical entity with cancer and tuberculosis (Riesco and Leyton, 1971) , confirmed here in relation to cancer, are still not sufficiently clear. However, if their presence is actually related with antineoplastic immunology, as has been suggested (Riesco and Leyton, 1971) , the findings presented here would be of value for a better definition of the population with high cancer risk. The results do not provide factors that might help to elucidate this hypothesis.
The present genetic study must be regarded as preliminary to an extension of the investigation of the leucocytic MPS phenotype in families of the general population. As it is, these preliminary results undoubtedly suggest the possibility of using this phenotype as a new genetic marker associated in a statistically highly significant way with the prevalence of cancer.
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